Tonisity Px Trial in China shows Excellent Effects on Newborn Piglet Growth Performance and Pre-weaning Mortality
A recent trial administering Tonisity Px to piglets from days two to eight of life, and three days before weaning yielded significant results on growth performance, pre-weaning survival and return on investment (ROI).

Dublin, Ireland (September 7, 2023) – Tonisity International Limited (“Tonisity”), an animal health and nutrition company based in Ireland, is pleased to announce additional positive effects of its flagship product, Tonisity PxÒ, an innovative isotonic protein solution for improving gut health and performance of piglets. In the farrowing room, the first week of the piglet’s life is critical, with 75% of pre-weaning mortality occurring during that period. Fast growth, efficient feed use, low costs, and high piglet survival are crucial for farm profits. A recent trial administering Tonisity Px to piglets from days two to eight of life, and three days before weaning yielded significant results on growth performance, pre-weaning survival and return on investment (ROI).

Extra weaning weight, fewer fall behinds, lower pre-weaning mortality

Tonisity recently completed a trial of Tonisity Px in China. The trial, which was conducted on a 3,167-sow farm in Huizhou Guangfeng Agriculture and Animal Husbandry Co., Ltd. in China, resulted in:

  • + 397 g extra weaning weight (+7.7%)
  • + 19 g/day extra daily weight gain before weaning (+12.6%)
  • 05% reduction in fall-behind pigs at weaning
  • 25% reduction in pre-weaning mortality

A statistical analysis demonstrated that those differences were significant. The ROI was 6.4:1 (based on less weak piglets, lower mortality and higher weaning weight) when all piglets were fed Tonisity Px from days two to eight of life and three days before weaning.

Mathieu Cortyl, Managing Director for Tonisity, comments, “We are very pleased to see these results are consistent with the Tonisity China weaning weight meta-analysis, which showed an average 210-470 g extra weaning weight across eight different studies. By improving the weaning survival rate, increasing the weight of weaned piglets and reducing the number fall-behinds, pig farmers can see direct economic benefits when using Tonisity Px on their farms”.

About Tonisity’s Swine Products

Tonisity Px is a patented isotonic protein drink that directly feeds the intestinal cells of livestock, such as piglets. This solution accelerates and increases the absorption of all nutrients into the body of the animal. Tonisity Px is administered to piglets in the first week of life and around weaning and is voluntarily consumed even by newborn piglets. The results are higher weight gain, lower mortality and less need for medications for these animals – all producing a high ROI for producers.

Tonisity is dedicated to research and has completed more than 200 swine trials throughout the world. In studies examining the effect of Tonisity Px on pre-weaning mortality, this parameter was an average reduction of 21%, which amounts to an extra pig for every three litters. Administration of Tonisity Px also resulted in higher weaning weights and 3 kg extra weight at the finishing stage, with an improved feed conversion rate. This technology results in a reliable 3:1 return on investment (5:5-1 in a recent China study1) at weaning and 5-6:1 at finishing.2

Tonisity PxW contains the same key bioactives aimed at nourishing the intestine and is delivered through ordinary waterlines to newly-weaned pigs, with no extra labour required. The weaning period and the first two to three weeks after weaning are a major danger period for pigs. Often, newly-weaned pigs struggle to maintain sufficient water intake. Reduced water intake correlates to reduced feed intake, which creates a growth lag and contributes to morbidity and mortality. 3,4

Tonisity PxW improves water intake by up to two times in the first few days after weaning. Pigs given Tonisity PxW for five days post-weaning had a 36% reduction in post-weaning mortality and an 18% decrease in post-weaning morbidity. Tonisity PxW has also been shown to improve end-nursery weights by 300 grams when compared to a competitor product.5 Trials indicate that the ROI on Tonisity PxW is a minimum of 4.5:1.

The Tonisity  swine products can also be given to pigs of any age at other stress points in production, such as weaning, before and after transport, and for sows, at farrowing or during lactation. While both products have been demonstrated to improve the performance of healthy pigs, trial data also shows that they are particularly useful in support of dehydration and recovery from illnesses such as porcine reproductive and respiratory syndrome and porcine epidemic diarrhea virus.6

Tonisity’s swine products are patented in all key markets and are currently being sold in Europe, Africa, Asia, North America, South America and Australia. Currently, the isotonic swine products are manufactured in Ireland.

For More Information on Tonisity

Tonisity is an animal health science and nutrition company based in Ireland that is currently focusing its patented technology in two specific markets: (1) isotonic products for the enhancement of swine production; and (2) novel companion animal nutrition products. Tonisity is focused on creating positive physiological changes by addressing the issue of intestinal health of young animals, thus improving their overall health, leading to better lifetime performance. With respect to novel companion animal products, Tonisity is poised to become the first mover and market leader in a targeted nutrition approach for pets – which is a rapidly growing market across the globe. For more information on Tonisity’s isotonic business, visit For more information on Tonisity’s companion animal business, visit


“Arie Halpern”

Arie Halpern
CEO and Chairman

Forward-Looking Statements

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect Tonisity’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information.

The forward-looking statements and information in this press release include information relating to the business plans of Tonisity, including global expansion, the processing of products in China and the development of new product lines in both the swine and companion animal product lines.

Such statements and information reflect the current views of Tonisity. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: Tonisity’s ability to raise capital to maintain its growth and business objectives, Tonisity’s ability to negotiate and enter into binding agreements with counterparties in geographic markets that are part of its expansion plans, Tonisity’s ability to operate in the Chinese market, changes in laws and regulations that could adversely affect Tonisity’s business, growth or results of operations, Tonisity’s ability to attract and retain customers and consumers and impacts of the COVID-19 pandemic.

There are a number of important factors that could cause Tonisity’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: limited business history of Tonisity; risks related to Tonisity’s corporate strategy including that previous and future acquisitions do not meet expectations; disruptions or changes in the credit or security markets; results of operation activities; unanticipated costs and expenses, fluctuations in commodity prices, and general market and industry conditions; protection of Tonisity’s intellectual property; disruption at any of Tonisity’s facilities including as a result of the current COVID-19 pandemic; effect of public health crises, including the current COVID-19 pandemic; Tonisity’s supply chain management; availability of suppliers of raw materials; limited or disrupted supply of key ingredients; the availability of key ingredients for Tonisity’s products; failure to expand production capacity; effect of product innovation; failure to retain current customers and/or recruit new customers potential volatility of share price; no assurance of active market for shares; dividends; global financial conditions; the effect of product labelling requirements; price of raw materials; consumer trends; publication of inaccurate or unfavourable research and reports; management and conflicts of interest.

Tonisity cautions that the foregoing list of material factors is not exhaustive. When relying on Tonisity’s forward-looking statements and information to make decisions, readers should carefully consider the foregoing factors and other uncertainties and potential events. Tonisity has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

The forward-looking information contained in this press release represents the expectations of Tonisity as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While Tonisity may elect to, it does not undertake to update this information at any particular time, except as required by applicable laws.



[1] China study 21-024-P-P

2 USA Study 18-014-P-P (PWM -22.8% & final weight +3.2 %): ROI = 3.2:1 at weaning and 5.9:1 at finishing;

UK Study 20-002-P-P (PWM -21% & final weight +2.5 %): ROI = 3.3:1 at weaning and 8.6:1 at finishing.

USA Study 17-061-P-P in disease situation (PRRS): ROI = 7.05:1

3 Pluske J, Le Dividich J, Verstegen M. Weaning the Pig – Concepts and Consequences. Weaning pig Wageningen Academic Publishers, 2003.

4 Kruse S, Traulsen I, Krieter J. Analysis of water, feed intake and performance of lactating sows. Livest Sci 2011;135:177–183.

5 US Study 20047-P-P

6 Trials 17-061-P-P USA, 20-038-P-P USA

Other Useful Resources
Greenfield, IN; Fort Collins, CO; Basel, Switzerland and Dublin, Ireland (November 15, 2022)
Elanco to Begin Distributing Tonisity’s Gut Enhancing Swine Products Following Strategic Partnership Agreement
Elanco Animal Health Incorporated global leader in animal health, is set to begin distributing Tonisity International Ltd.’s range of gut...